SNP-630 / Sinew Pharma - LARVOL DELTA

Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials. (PubMed, J Transl Med) - P2 | "SNP-630 and SNP-630-MS demonstrated favorable results in mice. SNP-630-MS showed excellent tolerability in mice and patients with MASH. Efficacy analyses indicated that SNP-630-MS improved liver steatosis and injury in patients with MASH, suggesting that SNP-630 and 630-MS are promising therapeutic options for MASH. Larger scale clinical trials remain warranted to assess the efficacy and safety of SNP-630 in MASH."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • CASP3 • CCL2 • COL1A1 • COL3A1 • CYP2E1 • TIMP1

SNP-630, a novel compound with multiple mechanisms, reverses liver inflammation and fibrosis in preclinical model and NASH phase 2 clinical trial (EASL-ILC 2023) - "These preclinical and phase 2 clinical data demonstrated that SNP-630 and its metabolites can suppress NASH fibrosis through DNL inhibition and inflammation. Figure: 1. Primary endpoint was met: ALT at week 12 were both significant reduced from baseline in the two dosage groups."

P2 data • Preclinical • Fibrosis • Hematological Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Non-alcoholic Steatohepatitis • Type 2 Diabetes Mellitus • ACTA2 • CCL2 • COL1A1 • IL1B • IL6 • PNPLA3 • TIMP1

SNP-630, a Novel Compound with Multiple Mechanisms, Reverses Non-alcoholic Steatohepatitis-Derived Liver Injury and Fibrosis (APASL 2023) - "These preclinical and phase 2 clinical data demonstrate that SNP-612 and SNP-630 can suppress NASH inflammation and fibrosis through novel and multiple mechanisms. 719"

Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Non-alcoholic Steatohepatitis • COL1A1 • COL3A1 • CYP2E1 • NF-κβ • TIMP1